Skip to main content
Premium Trial:

Request an Annual Quote

Life Science Insights Worldwide Therapeutic RNAi 2004-2014 Forecast and Analysis, Acuity Pharmaceuticals Cand5, and Mirus Online Store

Premium

Life Science Insights said it has published “Worldwide Therapeutic RNAi 2004-2014 Forecast and Analysis,” an analysis of the RNAi-based drugs market.

According to the company, the report includes an overview of RNAi technologies and a 10-year market forecast.

“The RNAi therapeutic market will grow to over $10 billion by 2014 if the first few RNAi therapies are successful in human clinical trials, which will start later this year,” Life Science Insights senior research editor Zachary Zimmerman said in a statement released this week.


Acuity Pharmaceuticals said earlier this month that it has already begun a phase I trial of its siRNA-based age-related macular degeneration drug Cand5.


Mirus has recently launched an online store.

All of the Mirus’ reagent products, including its TransIt nucleic acid delivery and Label It nucleic acid labeling technologies, can now be purchased on the company’s website.

Additional information can be found at http://www.mirusbiocorporation.com/Merchant2/merchant.mv?Screen=SFNT&Store_Code=MBC.

 

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.